Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host Disease

Release Date: March 28, 2018
Expiration Date: March 28, 2019
Media: Internet - based


Activity Overview

Graft-versus-host disease (GvHD) is a leading cause of morbidity and mortality among patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). An immune-mediated disorder, GvHD can manifest as an acute or chronic syndrome, or an overlap of the two, each of which presents unique challenges for clinicians who encounter them. The clinical consequences of these disorders and their rising incidence worldwide make it critical for hematologists who manage patients with hematological malignancies to improve knowledge and competence concerning GvHD.

This activity features video interviews with renowned experts who review and discuss aspects of GvHD important to cancer care providers, including its pathophysiology, assessment of patient risk for GvHD, diagnostic challenges, management recommendations, prevention and mitigation of adverse events, patient counseling considerations, and emerging therapeutic options.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

CME Activity Table of Contents

  • Module 1. Background and History of GvHD
  • Module 2. Biology and Novel Approaches to Acute GvHD
  • Module 3. Insights Into Chronic GvHD
  • Module 4. Impact of GvHD on Survivorship

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is intended for hematologists, medical oncologists, and other health care professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Summarize graft-versus-host disease (GvHD) pathogenesis and the evidence that informs best clinical practices to manage GvHD
  • Review current and prophylactic treatment regimens for GvHD
  • Describe current evidence regarding emerging therapies in the treatment of GvHD
  • Identify treatment-related risks associated with GvHD treatment strategies

Faculty, Staff, and Planners' Disclosures


John F. DiPersio, MD, PhD
Virginia E. and Samuel J. Golman Professor
Chief, Division of Oncology
Deputy Director, Alvin J. Siteman Cancer Center
Washington University School of Medicine
St Louis, MO

Disclosure:Consulting/Advisory Committees: Cellworks, Arch Pharma, RiverVest, Bioline, Asterias, Amphivena, and Bluebird; Employment/Salary: Washington University; Ownership Investment: Magenta.

Shernan Holtan, MD
Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, MN

Disclosure:Consultant: Incyte (one-time consulting)

Karl Peggs, MD
Senior Lecturer, Stem Cell Transplantation and Immunotherapy
UCL and Honorary Consultant in Hematology/Transplantation
University College Hospitals
London, UK

Disclosure: No relevant financial relationships with commercial interests to disclose.

Stefanie Sarantopoulos, MD, PhD
Associate Professor of Medicine
Assistant Professor of Immunology
Member of the Duke Cancer Institute
Durham, NC

Disclosure: Grant Research Support: Gilead Sciences (research grant for lab); Consultant: Gilead Sciences (active), Pharmacyclics (ad hoc).

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

PER Pulse Recap™

PER Pulse Recap (1 of 3)

This first of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr DiPersio about current treatment options and investigational therapies for acute GvHD, during which he discussed:
  • His approach toward a 52-year-old patient who developed grade IV GvHD (skin and gastrointestinal [GI] involvement), which developed suddenly over 1 week on day +40 after a matched unrelated donor, fludarabine/busulfan (Flu/Bu4) peripheral blood stem cell transplant was performed, with posttransplant cytarabine
  • Best practices for assessing a patient’s risk for developing GvHD post-transplantation
  • Key differences and similarities between acute GvHD, chronic GvHD, and overlap syndrome that drive management strategies
  • Individualizing prophylaxis for patients undergoing transplantation
  • Standards of care for prophylaxis, first-line treatment, and steroid-refractory acute GvHD
  • Emerging therapeutic targets, ongoing clinical trials, and recently reported data in acute GvHD
Monitoring for and managing treatment-related toxicities

PER Pulse Recap (2 of 3)

This second of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr Sarantopoulos about posttransplant chronic GvHD, during which she discussed:
  • Her approach toward a 40-year-old female patient who began experiencing signs of chronic GvHD (ie, ocular, vaginal, muscle/joint, skin changes) 1 year after a matched unrelated donor allogeneic stem cell transplant for acute myeloid leukemia
  • The importance of timely diagnosis and treatment
  • Current standard of care and important clinical advances in the management of chronic GvHD
  • Best practices toward integration of current guidelines for patient assessment and management into routine clinical practice
  • Investigational therapies in the pipeline

PER Pulse Recap (3 of 3)

This third of 3 PER Pulse™ Recaps summarizing the online program focuses on an interview with Dr Holtan about GvHD’s impact on survivorship care, during which she discussed:
  • Treatment goals for acute and chronic GvHD
  • The significance of host injuries induced by GvHD and its treatment to long-term outcomes and overall survivorship
  • Monitoring for and treating late effects of GvHD
  • Managing and reversing associated toxicities associated with GvHD and its treatments
  • The shifting focusing from donor cells to host factors to improve outcomes for patients with GvHD
  • Ongoing clinical trials and recently reported data

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By